Non-invasive cardiac imaging for evaluation of cardiotoxicity in cancer patients - early detection and follow-up

Cardiotoxicity is an increasingly important clinical entity that occurs as a result of untoward, and incompletely understood, effects on cardiac function. It is primarily caused by the anthracycline agents (doxorubicin, daunorubicin) but has also been observed with monoclonal antibody agents such as...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Gabriel Vorobiof, Cheri Silverstein
Formato:	article
Lenguaje:	EN
Publicado:	South African Heart Association 2017
Materias:	cardiotoxicity non-invasive cardiac imaging cancer Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/da5479581fcd4cb0840c87c8d24f1fbb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:da5479581fcd4cb0840c87c8d24f1fbb
record_format	dspace
spelling	oai:doaj.org-article:da5479581fcd4cb0840c87c8d24f1fbb2021-11-29T13:11:16ZNon-invasive cardiac imaging for evaluation of cardiotoxicity in cancer patients - early detection and follow-up10.24170/9-4-18291996-67412071-4602https://doaj.org/article/da5479581fcd4cb0840c87c8d24f1fbb2017-04-01T00:00:00Zhttps://www.journals.ac.za/index.php/SAHJ/article/view/1829https://doaj.org/toc/1996-6741https://doaj.org/toc/2071-4602Cardiotoxicity is an increasingly important clinical entity that occurs as a result of untoward, and incompletely understood, effects on cardiac function. It is primarily caused by the anthracycline agents (doxorubicin, daunorubicin) but has also been observed with monoclonal antibody agents such as trastuzumab and small molecule tyrosine kinase inhibitors. The most feared net result of these agents is left ventricular (LV) dysfunction resulting in symptomatic congestive heart failure (CHF). Other manifestations can include arrhythmias, pericardial constriction, valvulopathy and hypertension. Standard cardiac imaging techniques have largely focused on LV ejection fraction (LVEF) quantification. Contemporary cardiac imaging technologies now exist that are capable of evaluating for and detecting earlier stages of cardiotoxicity, including those which occur prior to changes in LVEF. Therapeutic algorithms have been devised to tailor chemotherapeutic regimens based on these results and have resulted in a dramatically reduced incidence of overt CHF.Gabriel VorobiofCheri SilversteinSouth African Heart Associationarticlecardiotoxicitynon-invasive cardiac imagingcancerDiseases of the circulatory (Cardiovascular) systemRC666-701ENSA Heart Journal, Vol 9, Iss 4, Pp 264-273 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	cardiotoxicity non-invasive cardiac imaging cancer Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	cardiotoxicity non-invasive cardiac imaging cancer Diseases of the circulatory (Cardiovascular) system RC666-701 Gabriel Vorobiof Cheri Silverstein Non-invasive cardiac imaging for evaluation of cardiotoxicity in cancer patients - early detection and follow-up
description	Cardiotoxicity is an increasingly important clinical entity that occurs as a result of untoward, and incompletely understood, effects on cardiac function. It is primarily caused by the anthracycline agents (doxorubicin, daunorubicin) but has also been observed with monoclonal antibody agents such as trastuzumab and small molecule tyrosine kinase inhibitors. The most feared net result of these agents is left ventricular (LV) dysfunction resulting in symptomatic congestive heart failure (CHF). Other manifestations can include arrhythmias, pericardial constriction, valvulopathy and hypertension. Standard cardiac imaging techniques have largely focused on LV ejection fraction (LVEF) quantification. Contemporary cardiac imaging technologies now exist that are capable of evaluating for and detecting earlier stages of cardiotoxicity, including those which occur prior to changes in LVEF. Therapeutic algorithms have been devised to tailor chemotherapeutic regimens based on these results and have resulted in a dramatically reduced incidence of overt CHF.
format	article
author	Gabriel Vorobiof Cheri Silverstein
author_facet	Gabriel Vorobiof Cheri Silverstein
author_sort	Gabriel Vorobiof
title	Non-invasive cardiac imaging for evaluation of cardiotoxicity in cancer patients - early detection and follow-up
title_short	Non-invasive cardiac imaging for evaluation of cardiotoxicity in cancer patients - early detection and follow-up
title_full	Non-invasive cardiac imaging for evaluation of cardiotoxicity in cancer patients - early detection and follow-up
title_fullStr	Non-invasive cardiac imaging for evaluation of cardiotoxicity in cancer patients - early detection and follow-up
title_full_unstemmed	Non-invasive cardiac imaging for evaluation of cardiotoxicity in cancer patients - early detection and follow-up
title_sort	non-invasive cardiac imaging for evaluation of cardiotoxicity in cancer patients - early detection and follow-up
publisher	South African Heart Association
publishDate	2017
url	https://doaj.org/article/da5479581fcd4cb0840c87c8d24f1fbb
work_keys_str_mv	AT gabrielvorobiof noninvasivecardiacimagingforevaluationofcardiotoxicityincancerpatientsearlydetectionandfollowup AT cherisilverstein noninvasivecardiacimagingforevaluationofcardiotoxicityincancerpatientsearlydetectionandfollowup
_version_	1718407376041672704

Non-invasive cardiac imaging for evaluation of cardiotoxicity in cancer patients - early detection and follow-up

Ejemplares similares